NCT06681441View on ClinicalTrials.gov

A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

December 24, 2024

Study Completion Date

December 24, 2024

Conditions
Healthy
Interventions
DRUG

QRL-101 Dose A

All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

DRUG

QRL-101 Dose B

All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

DRUG

Placebo

All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.

Trial Locations (1)

2333

Centre for Human Drug Research, Leiden

All Listed Sponsors
collaborator

Centre for Human Drug Research, Netherlands

OTHER

lead

QurAlis Corporation

INDUSTRY

NCT06681441 - A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants | Biotech Hunter | Biotech Hunter